Literature DB >> 15804702

Autoantibodies to heterogeneous nuclear ribonucleoproteins.

Roberto Caporali1, Serena Bugatti, Eleonora Bruschi, Lorenzo Cavagna, Carlomaurizio Montecucco.   

Abstract

Heterogeneous nuclear ribonucleoproteins (hnRNPs) are among the most abundant proteins in the eukaryotic cell nucleus and play a direct role in several aspects of the RNA life including splicing, export of the mature RNAs and translation. To date, approximately 30 proteins have been identified. A growing body of evidence points to hnRNPs as an important target of the autoimmune response in rheumatic diseases. Autoantibodies to A and B proteins of the hnRNP complex have been detected in late 1980s in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). Beyond their role as diagnostic test in clinical practice, these autoantibodies are starting to be regarded as important tools to obtain deeper insight into the pathogenesis of autoimmune rheumatic diseases. Furthermore, new anti-hnRNP antibodies have been recognized in the last ten years extending the spectrum of anti-hnRNP reactivity in different autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804702     DOI: 10.1080/08916930400022590

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  8 in total

1.  A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1.

Authors:  Eiichiro Noguchi; Yoichiro Homma; Xiaoyan Kang; Mihai G Netea; Xiaojing Ma
Journal:  Nat Immunol       Date:  2009-04-06       Impact factor: 25.606

2.  Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women.

Authors:  Jon J Ladd; Timothy Chao; Melissa M Johnson; Ji Qiu; Alice Chin; Rebecca Israel; Sharon J Pitteri; Jianning Mao; Mei Wu; Lynn M Amon; Martin McIntosh; Christopher Li; Ross Prentice; Nora Disis; Samir Hanash
Journal:  Cancer Res       Date:  2012-12-26       Impact factor: 12.701

3.  Single-cell exome sequencing identifies mutations in KCP, LOC440040, and LOC440563 as drivers in renal cell carcinoma stem cells.

Authors:  Chong Li; Song Wu; Zhao Yang; Xiaolong Zhang; Qi Zheng; Ling Lin; Zexiong Niu; Ruiqiang Li; Zhiming Cai; Lei Li
Journal:  Cell Res       Date:  2016-12-16       Impact factor: 25.617

4.  Loss of hnRNP A1 in murine skeletal muscle exacerbates high-fat diet-induced onset of insulin resistance and hepatic steatosis.

Authors:  Mingxia Zhao; Lihong Shen; Zijun Ouyang; Manru Li; Guoliang Deng; Chenxi Yang; Wei Zheng; Lingdong Kong; Xuefeng Wu; Xudong Wu; Wenjie Guo; Ye Yin; Qiang Xu; Yang Sun
Journal:  J Mol Cell Biol       Date:  2020-05-18       Impact factor: 6.216

5.  Proteomic analyses and identification of arginine methylated proteins differentially recognized by autosera from anti-Sm positive SLE patients.

Authors:  Hong-How Chang; Huan-Hsuan Hu; Yu-Jen Lee; Hung-Ming Wei; Ming-Chun Fan-June; Tsai-Ching Hsu; Gregory J Tsay; Chuan Li
Journal:  J Biomed Sci       Date:  2013-05-04       Impact factor: 8.410

6.  Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in Russian patients with rheumatoid arthritis and systemic sclerosis.

Authors:  Aleksey Maslyanskiy; Natalya Lazareva; Polina Olinek; Peter Schierack; Christian Hentschel; Juliane Cuccato; Dimitrios P Bogdanos; Sergey V Lapin; Dirk Roggenbuck
Journal:  J Immunol Res       Date:  2014-05-04       Impact factor: 4.818

7.  HnRNP A1 is Involved in Deep Vein Thrombosis Patients with Behçet's Disease.

Authors:  Peng Chen; Chunyan Zhang; Chen Liu; Liyun Zhang; Chunhe Yang; Guangyu Chen; Dan Ma; Yaping Tian; Hongwu Du
Journal:  EBioMedicine       Date:  2016-03-10       Impact factor: 8.143

8.  HNRNPA1 interacts with a 5'-flanking distal element of interleukin-6 and upregulates its basal transcription.

Authors:  D Zheng; J Worthington; J F Timms; P Woo
Journal:  Genes Immun       Date:  2013-08-29       Impact factor: 2.676

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.